Interesting read thanks quacker. Specially considering one of the limitations with the currrent range of immunotherapy drugs seems to be the collateral damage caused to healthy tissue by allowing the immune system to attack tissue by blocking receptors.
It's a massive market, and expensive for patients. Treatments coming in at $150,000 per year or there abouts. Interesting read about Merck's new drug below:
http://online.wsj.com/articles/fda-approves-mercks-cancer-drug-1409856320
HSV Vaccine Results, page-88
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.22 |
Change
0.740(6.45%) |
Mkt cap ! $258.3M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $12.25 | $11.49 | $395.2K | 33.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $11.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.22 | 127 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |